نتایج جستجو برای: teriparatide

تعداد نتایج: 877  

Journal: :Head & neck 2011
Jang-Jaer Lee Shih-Jung Cheng Jiiang-Huei Jeng Chun-Pin Chiang Hon-Ping Lau Sang-Heng Kok

BACKGROUND The management of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is challenging and controversial. At present, there is no established medication treatment for the disease. METHODS A 78-year-old osteoporotic woman with osteonecrosis of the mandible related to alendronate therapy was referred for treatment. The disease was unresponsive to conservative therapy, including an...

2012
Pooja Raghavan Elena Christofides

Bone fractures are one of the leading causes of emergency room visits worldwide, with approximately 8 million bony fractures occurring annually in the US alone. Although the majority of fractures do not cause significant long-term morbidity and mortality, approximately 10% of these fractures result in impaired fracture healing, drastically affecting quality of life in affected patients. By incr...

2016
Atsushi Nishikawa Takehiro Ishida Masanori Taketsuna Fumito Yoshiki Hiroyuki Enomoto

This postmarketing surveillance study assessed the safety and effectiveness of teriparatide in patients with osteoporosis at high risk of fracture in Japan. The patients received teriparatide 20 μg daily by subcutaneous injection, for a maximum of 24 months. Safety and effectiveness analyses were based on data from 1,847 patients who were predominantly female (92.6%) with a mean age of 75.4 yea...

Journal: :The Journal of bone and joint surgery. American volume 2016
Per Aspenberg Jorge Malouf Umberto Tarantino Pedro A García-Hernández Costantino Corradini Søren Overgaard Jan J Stepan Lars Borris Eric Lespessailles Frede Frihagen Kyriakos Papavasiliou Helmut Petto José Ramón Caeiro Fernando Marin

BACKGROUND Osteoporosis drugs might affect fracture-healing. We therefore studied the effects of teriparatide in comparison with risedronate on recovery after pertrochanteric hip fractures. METHODS The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pe...

2015
Toshihiro Sugiyama Tetsuya Torio Tsuyoshi Sato Masahito Matsumoto Yoon Taek Kim Hiromi Oda

SKELETAL ADAPTATION TO MECHANICAL STRAIN IN HUMANS Several lines of clinical evidence (1–3) suggest that the adult skeleton in humans continuously responds to change in mechanical environment to maintain resultant “elastic” deformation (strain) of bone; increased or decreased bone strain would normally induce bone gain or loss, respectively. Indeed, skeletal adaptation to mechanical strain, kno...

Journal: :Lancet 2013
Richard Eastell Jennifer S Walsh

www.thelancet.com Published online May 15, 2013 http://dx.doi.org/10.1016/S0140-6736(13)60984-8 1 Some therapies licensed to treat osteoporosis work by inhibiting bone turnover (anticatabolic agents) and some by stimulating bone formation (anabolic agents). In The Lancet, Joy Tsai and colleagues report an exciting new approach in which an anticatabolic drug, denosumab, is combined with an anabo...

2009
Gabriele Lehmann Undine Ott Jörg Maiwald Gunter Wolf

A 33-year-old male patient suffered from adynamic bone disease because of parathyroidectomy due to tertiary hyperparathyroidism. Histomorphometric analysis of bone biopsies taken before and 8 months after treatment with teriparatide (human parathyroid hormone 1-34 of recombinant DNA origin) for 18 months is demonstrated. A considerable increase in mineralized bone volume and also stimulated bon...

2017
Håkan Ledin Lars Good Torsten Johansson Per Aspenberg

Background and purpose - Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fixation. We used radiostereometric analysis (RSA) to investigate whether teriparatide influences ...

2013
Claus-C Glüer Fernando Marin Johann D Ringe Federico Hawkins Rüdiger Möricke Nikolaos Papaioannu Parvis Farahmand Salvatore Minisola Guillermo Martínez Joan M Nolla Christopher Niedhart Nuria Guañabens Ranuccio Nuti Emilio Martín-Mola Friederike Thomasius Georgios Kapetanos Jaime Peña Christian Graeff Helmut Petto Beatriz Sanz Andreas Reisinger Philippe K Zysset

Data on treatment of glucocorticoid-induced osteoporosis (GIO) in men are scarce. We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations. Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months. Primary objective was to compare l...

2015
Ling-Xiao Chen Zhi-Rui Zhou Yu-Lin Li Guang-Zhi Ning Tian-Song Zhang Di Zhang Shi-Qing Feng Bart O. Williams

CONTEXT The preferred treatment for osteoporosis in men is debated, and pairwise meta-analysis cannot obtain hierarchies of these treatments. OBJECTIVE The objective of this study was to integrate the evidence and provide hierarchies of eight drugs based on their effect on the bone mineral density in the lumbar spine (BMD in LS) and the fracture rate. DATA SOURCES Eligible studies were iden...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید